Recently, it was learned from Shanghai Fosun Pharma that Fosun Industrial (Hong Kong) Co., Ltd., a subsidiary of Fosun Pharma Holding, officially signed a sales agreement with Taiwan Semiconductor Manufacturing Company,  FOXCONN, YongLin, and Zuellig Pharma, respectively, to sell a total of 10 million doses of  novel COVID-mRNA vaccine to Zuellig Pharma, which was commissioned by TSMC, FOXCONN, and YongLin. This batch of vaccine will be donated by the buyers to disease control agencies in Taiwan for local vaccination.

Yifang Wu , Chairman and CEO of Fosun Pharma, said, “We are very pleased to see that this vaccine jointly developed by Fosun Pharma and BioNTech SE can play a positive role in the prevention and control of the epidemic in Taiwan. We will work with our partners to make safe and effective vaccines supplied to Taiwan as soon as possible to jointly safeguard the lives and health of Taiwan compatriots and help Taiwan compatriots return to normal life as soon as possible."

“Bringing a safe and effective vaccine to more people around the world has been a common goal of BioNTech SE and our partners since the outbreak of COVID-19,” said Ugur Sahin, CEO and Co-Founder of BioNTech SE. “In the meantime, we will continue to evaluate the effectiveness of the vaccine against the new novel coronavirus mutant.”

On March 16, 2020, Fosun Pharma and BioNTech SE jointly announced a strategic cooperation agreement under which Fosun Pharma will be authorized by BioNTech SE to exclusively develop and commercialize a vaccine product for novel coronavirus based on its proprietary mRNA technology platform in mainland of China, Hong Kong, Macao and Taiwan.